Amylyx (AMLX) CFO Sells Shares to Cover RSU Taxes; Holds 280,430 Shares
Rhea-AI Filing Summary
James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale on 09/30/2025 of 10,558 shares of common stock at a weighted average price of $14.6477. The filing states the sales were automatic to cover tax withholding related to the vesting of restricted stock units and were not at the reporting person’s discretion. After the reported transactions, Mr. Frates beneficially owned 280,430 shares directly and held an additional 15,459 and 11,072 shares indirectly through two trusts for which he is trustee. The form is signed by an attorney-in-fact on 10/02/2025.
Positive
- 280,430 shares remain directly beneficially owned by the CFO after the transaction
- 15,459 and 11,072 shares are held indirectly in trusts where the reporting person is trustee
Negative
- 10,558 shares were sold on 09/30/2025, reducing the reporting person’s direct holdings
- Sale executed at a weighted average price of $14.6477, with individual trades ranging $14.35 to $15.075
Insights
Automatic RSU tax-sale; executive retains sizeable stake
The report shows a 09/30/2025 sale of 10,558 shares at a weighted average price of $14.6477 coded as a tax-withholding sale tied to vested restricted stock units. The filing explicitly states these sales were automatic and not at the reporting person’s discretion, which clarifies that the transaction was administrative rather than a voluntary divestiture.
Following the sale, the reporting person still holds 280,430 shares directly plus 15,459 and 11,072 shares indirectly in two trusts where he serves as trustee. That level of retained ownership indicates continued alignment with shareholders while complying with tax obligations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10,558 | $14.6477 | $155K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
